Andrew Doig

Prof. Andrew Doig


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2018 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
SPSudeep Pushpakom
Sudeep Pushpakom
Francesco IorioFrancesco Iorio
Francesco Iorio
PEPatrick Eyers
Patrick Eyers
KEK. Jane Escott
K. Jane Escott
SHShirley Hopper
Shirley Hopper
MPMunir Pirmohamed
Munir Pirmohamed
Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compounds, with potentially lower overall development costs and shorter development timelines. Various data-driven and experimental approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technological and regulatory challenges that need to be addressed. In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.

1 July 2003 in Journal of Molecular Biology
Verified
Journal Article
Closed access
PDPaul D. Dobson
Paul D. Dobson
ADAndrew Doig
Andrew Doig


19 March 2015 in Chemical Reviews
Verified
Journal Article
Closed access
JNJessica Nasica-Labouze
Jessica Nasica-Labouze
PNPhuong H. Nguyen
Phuong H. Nguyen
FSFabio Sterpone
Fabio Sterpone
OBOlivia Berthoumieu
Olivia Berthoumieu
NBNicolae-Viorel Buchete
Nicolae-Viorel Buchete
PDPhilippe Derreumaux
Philippe Derreumaux

21 January 2009 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TBTala M. Bakheet
Tala M. Bakheet
ADAndrew Doig
Andrew Doig
Motivation: We analysed 148 human drug target proteins and 3573 non-drug targets to identify differences in their properties and to predict new potential drug targets. Results: Drug targets are rare in organelles; they are more likely to be enzymes, particularly oxidoreductases, transferases or lyases and not ligases; they are involved in binding, signalling and communication; they are secreted; and have long lifetimes, shown by lack of PEST signals and the presence of N-glycosylation. This can be summarized into eight key properties that are desirable in a human drug target, namely: high hydrophobicity, high length, SignalP motif present, no PEST motif, more than two N-glycosylated amino acids, not more than one O-glycosylated Ser, low pI and membrane location. The sequence features were used as inputs to a support vector machine (SVM), allowing the assignment of any sequence to the drug target or non-target classes with an accuracy in the training set of 96%. We identified 668 proteins (23%) in the non-target set that have target-like properties. We suggest that drug discovery programmes would be more likely to succeed if new targets are chosen from this set or their homologues. Contact:andrew.doig@manchester.ac.uk Supplementary Information: Supplementary data are available at Bioinformatics online.

1 February 2015 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
ADAndrew Doig
Andrew Doig
PDPhilippe Derreumaux
Philippe Derreumaux